DrugPatentWatch Database Preview
Iohexol - Generic Drug Details
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What are the generic drug sources for iohexol and what is the scope of freedom to operate?
Iohexol
is the generic ingredient in ten branded drugs marketed by Interpharma Praha As and Ge Healthcare, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.There are three drug master file entries for iohexol. Three suppliers are listed for this compound.
Summary for iohexol
| US Patents: | 0 |
| Tradenames: | 10 |
| Applicants: | 2 |
| NDAs: | 3 |
| Drug Master File Entries: | 3 |
| Suppliers / Packagers: | 3 |
| Bulk Api Vendors: | 70 |
| Clinical Trials: | 47 |
| Patent Applications: | 2,628 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | iohexol at DailyMed |
Recent Clinical Trials for iohexol
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute (NCI) | N/A |
| Vanderbilt University Medical Center | Phase 4 |
| VU University Medical Center | Phase 4 |
Pharmacology for iohexol
| Drug Class | Radiographic Contrast Agent |
| Mechanism of Action | X-Ray Contrast Activity |
Medical Subject Heading (MeSH) Categories for iohexol
Synonyms for iohexol
| 1-N,3-N-bis(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamide |
| 1,3-Benzenedicarboxamide, 5-(acetyl(2,3-dihydroxypropyl)amino)-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo- |
| 1,3-benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo- |
| 1,3-Benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-N1,N3-bis(2,3-dihydroxypropyl)-2,4,6-triiodo- |
| 108I950 |
| 4419T9MX03 |
| 5-(N-2-3-DIHYDROXYPROPYL-ACETMIDO)-2,4,6-TRIIODO-N,N'-bis-(2,3-DIHYDROXYPROPYL)-ISOPHTHALAMIDE |
| 5-(N-2,3-Dihydroxypropylacetamido)-2,4,6-triiodo-N,N inverted exclamation marka-bis(2,3-dihydroxypropyl)isophthalamide |
| 5-(N-2,3-Dihydroxypropylacetamido)-2,4,6-triiodo-N,N'-bis(2,3-dihydroxypropyl)isophthalamide |
| 5-(N-dhp-acetamido)-2,4,6-triiodo-N,N'-B is-dhp-isophthalami |
| 5-[acetyl(2,3-dihydroxypropyl)amino]-1-N,3-N-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide |
| 5-[acetyl(2,3-dihydroxypropyl)amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide |
| 5-[Acetyl(2,3-dihydroxypropyl)amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide |
| 5-[acetyl(2,3-dihydroxypropyl)amino]-N1,N3-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-benzene-1,3-dicarboxamide |
| 5-[acetyl(2,3-dihydroxypropyl)amino]-N1,N3-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide |
| 5-[N-(2,3-Dihydroxypropyl)acetamido]-2,4,6-triiodo-N,N'-bis(2,3-dihydroxypropyl)isophthalamide |
| 5-[n-(2,3-Dihydroxypropyl)acetamido]-2,4,6-triiodo-N,N'-bis(2,3-dihydroxypropyl)isophthalamidesolution |
| 66108-95-0 |
| A835339 |
| AB0012347 |
| AC-1934 |
| AC1L1GKZ |
| AKOS015895399 |
| ALBB-028959 |
| AN-14471 |
| API0003012 |
| AS-12699 |
| BC209326 |
| BCBcMAP01_000051 |
| BPBio1_000511 |
| BRN 2406632 |
| BSPBio_000463 |
| C-23546 |
| C19H26I3N3O9 |
| CAS-66108-95-0 |
| CC-29572 |
| CCG-220512 |
| CHEBI:31709 |
| CHEMBL1200455 |
| CS-2811 |
| CTK8G0334 |
| D01817 |
| DB01362 |
| DSSTox_CID_3157 |
| DSSTox_GSID_23157 |
| DSSTox_RID_76895 |
| DTXSID6023157 |
| EBD45459 |
| EC 266-164-2 |
| EINECS 266-164-2 |
| Exypaque |
| FT-0627276 |
| Histodenz |
| Histodenz(TM), nonionic density gradient medium |
| Histodenz™ |
| Histodenz|||Nycodenz |
| HMS1569H05 |
| HMS2096H05 |
| HMS2235D07 |
| HMS3369O04 |
| HMS3713H05 |
| HY-B0594 |
| I06-0659 |
| I0903 |
| Iohexol (JP17/USP/INN) |
| Iohexol [USAN:BAN:INN:JAN] |
| Iohexol [USAN:USP:INN:BAN:JAN] |
| Iohexol for peak identification, European Pharmacopoeia (EP) Reference Standard |
| Iohexol injection (JP17) |
| Iohexol, analytical standard |
| Iohexol, European Pharmacopoeia (EP) Reference Standard |
| Iohexol, Pharmaceutical Secondary Standard; Certified Reference Material |
| Iohexol, United States Pharmacopeia (USP) Reference Standard |
| Iohexolum |
| Iohexolum [INN-Latin] |
| KS-00001F7T |
| LS-29715 |
| MLS001332585 |
| MLS001332586 |
| MLS002153854 |
| MolPort-003-931-371 |
| N,N'-Bis(2,3-dihydroxypropyl)-5-(N-(2,3-dihydroxypropyl)acetamido)-2,4,6-triiodoisophthalamide |
| n,n'-bis(2,3-dihydroxypropyl)-5-[n-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodoisophthalamide |
| N1,N3-bis(2,3-dihydroxypropyl)-5-(N-(2,3-dihydroxypropyl)acetamido)-2,4,6-triiodoisophthalamide |
| N1,N3-bis(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamide |
| N1,N3-bis[2,3-bis(oxidanyl)propyl]-5-[2,3-bis(oxidanyl)propyl-ethanoyl-amino]-2,4,6-tris(iodanyl)benzene-1,3-dicarboxamide |
| NCGC00166000-01 |
| NCGC00166000-02 |
| NCGC00166000-04 |
| NTHXOOBQLCIOLC-UHFFFAOYSA-N |
| Nycodenz |
| Omnipaque |
| Omnipaque (TN) |
| Omnipaque 180 |
| Omnipaque 210 |
| Omnipaque 240 |
| Omnipaque 70 |
| Prestwick_802 |
| Prestwick0_000512 |
| Prestwick1_000512 |
| Prestwick2_000512 |
| Prestwick3_000512 |
| SC-17734 |
| SCHEMBL26501 |
| SMP1_000152 |
| SMR000857075 |
| SPBio_002384 |
| SR-01000838892 |
| SR-01000838892-2 |
| Tox21_112286 |
| Tox21_112286_1 |
| UNII-4419T9MX03 |
| WIN 39424 |
| WIN-39424 |
| ZX-AN079772 |
US Patents and Regulatory Information for iohexol
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ge Healthcare | OMNIPAQUE 9 | iohexol | SOLUTION;ORAL | 018956-008 | Apr 17, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Ge Healthcare | OMNIPAQUE 70 | iohexol | SOLUTION;URETHRAL | 018956-007 | Jun 1, 1994 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Ge Healthcare | OMNIPAQUE 210 | iohexol | INJECTABLE;INJECTION | 018956-006 | Jun 30, 1989 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for iohexol
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ge Healthcare | OMNIPAQUE 70 | iohexol | SOLUTION;URETHRAL | 018956-007 | Jun 1, 1994 | Start Trial | Start Trial |
| Ge Healthcare | OMNIPAQUE 180 | iohexol | SOLUTION;INJECTION, ORAL, RECTAL | 018956-001 | Dec 26, 1985 | Start Trial | Start Trial |
| Ge Healthcare | OMNIPAQUE 300 | iohexol | SOLUTION;INJECTION, ORAL, RECTAL | 018956-003 | Dec 26, 1985 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2019 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.